Clinical Trials Logo

Anti-LGI1 Encephalitis clinical trials

View clinical trials related to Anti-LGI1 Encephalitis.

Filter by:
  • None
  • Page 1

NCT ID: NCT04106765 Not yet recruiting - Clinical trials for Anti-LGI1 Encephalitis

LGI1-antibody Patients Follow-up

evoLGI1
Start date: October 30, 2019
Phase:
Study type: Observational

Autoimmune encephalitis involve autoantibodies targeting central nervous system, and particularly the synapse or its structure like for LGI1 protein. Anti-LGI1 encephalitis is revealed by an inflammation of the limbic system, with mainly temporal lobe, faciobrachial dystonic or generalized seizures, and cognitive disorders. This disease is rare and its clinical, EEG and radiological characterisation is not sufficiently established. The investigators will evaluate these three aspects for the anti-LGI1 cohort of patients of the National Reference Center of autoimmune encephalitis.